Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells
Copyright policy )Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells
Leukemia : normal and malignant hemopoiesis (2024). doi:10.1038/s41375-024-02320-9
Published by Springer Nature, London
- RWTH Aachen University Germany
- RWTH Aachen University (Medical Faculty) Germany
Niacinamide, Letter, Fusion Proteins, bcr-abl, 610, Mice, Letter ; Neoplastic Stem Cells/pathology [MeSH] ; Proto-Oncogene Proteins c-abl/genetics [MeSH] ; Pyrazoles/therapeutic use [MeSH] ; Fusion Proteins, bcr-abl/antagonists ; Neoplastic Stem Cells/metabolism [MeSH] ; /631/67/395 ; /13/100 ; Blast Crisis/drug therapy [MeSH] ; Niacinamide/analogs ; letter ; /13/31 ; /631/67/1059/602 ; Fusion Proteins, bcr-abl/genetics [MeSH] ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy [MeSH] ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology [MeSH] ; Neoplastic Stem Cells/drug effects [MeSH] ; Protein Kinase Inhibitors/pharmacology [MeSH] ; Humans [MeSH] ; Pyrazoles/pharmacology [MeSH] ; /692/308/2778 ; Animals [MeSH] ; Proto-Oncogene Proteins c-abl/metabolism [MeSH] ; /64/60 ; Protein Kinase Inhibitors/therapeutic use [MeSH] ; Mice [MeSH] ; /45/23 ; Blast Crisis/pathology [MeSH] ; Proto-Oncogene Proteins c-abl/antagonists, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplastic Stem Cells, Humans, Animals, Pyrazoles, Blast Crisis, Proto-Oncogene Proteins c-abl, Protein Kinase Inhibitors, info:eu-repo/classification/ddc/610
Niacinamide, Letter, Fusion Proteins, bcr-abl, 610, Mice, Letter ; Neoplastic Stem Cells/pathology [MeSH] ; Proto-Oncogene Proteins c-abl/genetics [MeSH] ; Pyrazoles/therapeutic use [MeSH] ; Fusion Proteins, bcr-abl/antagonists ; Neoplastic Stem Cells/metabolism [MeSH] ; /631/67/395 ; /13/100 ; Blast Crisis/drug therapy [MeSH] ; Niacinamide/analogs ; letter ; /13/31 ; /631/67/1059/602 ; Fusion Proteins, bcr-abl/genetics [MeSH] ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy [MeSH] ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology [MeSH] ; Neoplastic Stem Cells/drug effects [MeSH] ; Protein Kinase Inhibitors/pharmacology [MeSH] ; Humans [MeSH] ; Pyrazoles/pharmacology [MeSH] ; /692/308/2778 ; Animals [MeSH] ; Proto-Oncogene Proteins c-abl/metabolism [MeSH] ; /64/60 ; Protein Kinase Inhibitors/therapeutic use [MeSH] ; Mice [MeSH] ; /45/23 ; Blast Crisis/pathology [MeSH] ; Proto-Oncogene Proteins c-abl/antagonists, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplastic Stem Cells, Humans, Animals, Pyrazoles, Blast Crisis, Proto-Oncogene Proteins c-abl, Protein Kinase Inhibitors, info:eu-repo/classification/ddc/610
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).4 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!